The research group of Jörn Piel at ETH Zurich, together with Edgars Lakis and Daniel Richter, is using a new approach in chemistry to manufacture and improve cancer treatments.
It seeks to enable researchers to improve the efficacy of a class of cancer treatments known as antibody-drug conjugates.
The prototype chemical reaction has already been developed; the research team is currently working on the production of prototype medicines for testing in preclinical trials.
During their treatment, cancer patients have to deal with severe side-effects. The TyrEx approach will hopefully make their journey a little easier in future.